Skip to main content
. Author manuscript; available in PMC: 2018 Jan 29.
Published in final edited form as: Oncogene. 2016 Apr 4;35(42):5527–5538. doi: 10.1038/onc.2016.93

Fig 5. Increased PRR14 makes cells more sensitive to PI3K/Akt/mTOR signaling pathway inhibitors.

Fig 5

(A) H1299 cells transfected with PRR14 or empty vector were treated with indicated inhibitors for 1.5h, and the PI3K/Akt/mTOR signaling pathway activity was detected through immunostaining p-AKT (S308). (B) Both H1299 PRR14 cell line and its control H1299 V were treated with 10uM mTOR inhibitor, LY294002, and analyzed for cell activity by Alamar Blue Assay at indicated time points. Alternatively, both cell lines were treated with mTOR inhibitor, Torin2 (C) or MAPK inhibitor, U0126 (D), at different doses for 48h. Then cell activity was measured by Alamar blue assay and statistically analyzed by two-tailed student's t-test Statistical analysis (*P<0.05, ** P<0.01, *** P<0.001).